Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects

NCT00903682 is registered in ClinicalTrials.gov with Janssen-Cilag International NV as lead sponsor.

NCT NCT00903682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00903682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects
Lead sponsor
Janssen-Cilag International NV
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
January 31, 2011
Enrollment
157 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

acquired immunodeficiency syndrome, hiv, hiv infection